Clinical trial of levosimendan in the treatment of chronic obstructive pulmonary disease with cardiac insufficiency
10.13699/j.cnki.1001-6821.2017.16.003
- VernacularTitle:左西孟旦注射液治疗慢性阻塞性肺疾病伴心功能不全的临床研究
- Author:
Wei-Gen OU
1
;
Hong-Liu CAI
Author Information
1. 杭州市余杭区第一人民医院急诊和重症医学科
- Keywords:
levosimendan;
terbutaline sulfate;
chronic obstructive pulmonary disease;
cardiac insufficiency
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(16):1527-1530
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of levosimendan combined with terbutaline sulfate in the treatment of chronic obstructive pulmonary disease with cardiac insufficiency.Methods A total of 88 patients were randomly divided into control group and treatment group,with 44 cases in each group.Patients in both groups were given conventional treatment and symptomatic treatment.Patients in control group were given inhalation budesonide suspension liquid 1 mg + terbutaline sulfate atomized liquid 5 mg in jet atomizer,oxygen driven atomization inhalation,twice a day.Patients in treatment group were given levosimendan 0.1 μg · kg-1 · min-1 infusion,continue medication 24 h on the basis of control group.All patients were treated for 7 d.The clinical efficacy,troponin T,myocardial enzyme spectrum,cardio-pulmonary function and adverse drug reactions in two groups were observed.Results After treatment,the total effective rates in treatment group and control group were 88.64％ (39/44 cases),70.45％ (31/44 cases),with significant difference (P ＜ 0.05).The levels of troponin T,creatine kinase,creatine kinase isoenzyme,lactate dehydrogenase,left ventricular end diastolic diameter,forced expiratory volume in one second,forced expiratory volume in one second/ forced vital capacity (FEV1/FVC),left ventricular ejection fraction,maximum walking distance within 6 min in control group were (0.48 ±0.06) μg · L-1,(189.29 ±21.30) U · L-1,(11.34 ± 1.71)U·L-1,(159.29±17.11) U L-1,(50.29 ± 5.79) mm,(1.35 ± 0.19) L,(60.93 ± 7.09)％,(42.39 ±4.58)％,(260.39 ± 29.21)m,had significant difference with those in treatment group,which were (0.18 ±0.03)μg · L-1,(130.27 ± 16.11)U · L-1,(8.87 ± 1.09) U · L-1,(138.70 ± 14.51) U · L-1,(47.01 ±5.01)mm,(1.70±0.23) L,(76.94±8.58)％,(51.29±5.71)％,(324.29 ±35.16)m (P＜0.05).The adverse drug reactions in treatment group were palpitations,headache,dizziness,total incide nce rate of adverse drug reactions was 6.82％ (3/44 cases).The adverse drug reactions in control group were orthostatic hypotension,hyponatremia,arrhythmia,thirst,total incidence rate was 11.36％ (5/44 cases),with no significant difference (P ＞0.05).Conclusion Levosimendan combined with terbutaline sulfate in the treatment of chronic obstructive pulmonary disease with cardiac insufficiency has a higher clinical efficacy,with high safety.
